As this share has grown, however, Novo shareholders should be aware that GLP-1 agonists have become an increasingly large ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Smoothie King, a franchise that specializes in selling smoothies, recently launched a "GLP-1 Support Menu," made specifically ...

Originally intended as a treatment for diabetes, GLP-1 drugs like Ozempic could be set to turn the food and drink industry ...

Patients taking Ozempic and other trendy injectables are going under the ... At the heart of these medications are two key ...

One in eight American adults, about 12%, has taken Ozempic or a similar drug for diabetes or weight loss, recent research ...

Westend61/Getty Images The use of GLP-1 medications such as semaglutide — more widely known under the brand names of Ozempic ...

The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...

It can be harder to lose weight after a certain age, which is why GLP-1 medications can be incredibly useful. That's where ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...

Ozempic works by mimicking a naturally occurring hormone called GLP-1 (glucagon-like peptide-1), which plays a crucial role ...